SEARCH:   Advanced

Blood, 1 November 2008, Vol. 112, No. 9, pp. 3591-3593. Prepublished online as a Blood First Edition Paper on July 8, 2008; DOI 10.1182/blood-2008-02-141598. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2008-02-141598v1 112/9/3591    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Rosiñol, L. Articles by Bladé, J. Search for Related Content PubMed PubMed Citation Articles by Rosiñol, L. Articles by Bladé, J. Related Collections Neoplasia Transplantation Free Research Articles Brief Reports Clinical Trials and Observations Related Articles in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Brief Report A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma Laura Rosiñol1, José Antonio Pérez-Simón2, Anna Sureda3, Javier de la Rubia4, Felipe de Arriba5, Juan José Lahuerta6, José David González7, Joaquín Díaz-Mediavilla8, Belén Hernández9, Javier García-Frade10, Dolores Carrera11, Angel León12, Miguel Hernández13, Pascual Fernández Abellán14, Juan Miguel Bergua15, Jesús San Miguel2, Joan Bladé1, for Programa para el Estudio y la Terapéutica de las Hemopatías Malignas y Grupo Español de Mieloma (PETHEMA/GEM) 1 Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona; 2 Hospital Clínico/Centro de Investigación del Cáncer, Salamanca; 3 Hospital de la Santa Creu i Sant Pau, Barcelona; 4 Hospital La Fe, Valencia; 5 Hospital Morales Messeguer, Murcia; 6 Hospital Doce de Octubre, Madrid; 7 Hospital Materno-Insular, Las Palmas de Gran Canaria; 8 Hospital Clínico San Carlos, Madrid; 9 Hospital General Ciudad Real, Ciudad Real; 10 Hospital Rio Hortega, Valladolid; 11 Hospital de Asturias, Oviedo; 12 Hospital de Jerez de la Frontera, Jerez; 13 Hospital Universitario Canarias, Sta Cruz de Tenerife; 14 Hospital de Alicante, Alicante; and 15 Hospital San Pedro de Alcántara, San Pedro de Alcántara, Spain One hundred ten patients with multiple myeloma (MM) failing to achieve at least near-complete remission (nCR) after a first autologous stem cell transplantation (ASCT) were scheduled to receive a second ASCT (85 patients) or a reduced-intensity-conditioning allograft (allo-RIC; 25 patients), depending on the human leukocyte antigen (HLA)–identical sibling donor availability. There was a higher increase in complete remission (CR) rate (40% vs 11%, P = .001) and a trend toward a longer progression-free survival (PFS; median, 31 months vs not reached, P = .08) in favor of allo-RIC. In contrast, it was associated with a trend toward a higher transplantation-related mortality (16% vs 5%, P = .07), a 66% chance of chronic graft-versus-host disease and no statistical difference in event-free survival and overall survival. Although the PFS plateau observed with allo-RIC is very encouraging, this procedure is associated with high morbidity and mortality, and therefore it should still be considered investigational and restricted to well-designed prospective clinical trials. This trial is registered at ClinicalTrials.gov ID number NCT00560053 [ClinicalTrials.gov] CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Articles in Blood Online: Is more better in myeloma? Guido Tricot Blood 2008 112: 3532. [Full Text] [PDF] Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma Philippe Moreau, Frédéric Garban, Michel Attal, Mauricette Michallet, Gérald Marit, Cyrille Hulin, Lotfi Benboubker, Chantal Doyen, Mohamad Mohty, Ibrahim Yakoub-Agha, Serge Leyvraz, Philippe Casassus, Hervé Avet-Loiseau, Laurent Garderet, Claire Mathiot, and Jean-Luc Harousseau, on behalf of the IFM group Blood 2008 112: 3914-3915. [Full Text] [PDF] This article has been cited by other articles: A. K. Stewart Reduced-intensity allogeneic transplantation for myeloma: reality bites Blood, April 2, 2009; 113(14): 3135 - 3136. [Full Text] [PDF] M. Rotta, B. E. Storer, F. Sahebi, J. A. Shizuru, B. Bruno, T. Lange, E. D. Agura, P. A. McSweeney, M. A. Pulsipher, P. Hari, et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting Blood, April 2, 2009; 113(14): 3383 - 3391. [Abstract] [Full Text] [PDF] B. Bruno, M. Rotta, F. Patriarca, D. Mattei, B. Allione, F. Carnevale-Schianca, R. Sorasio, A. Rambaldi, M. Casini, M. Parma, et al. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo Blood, April 2, 2009; 113(14): 3375 - 3382. [Abstract] [Full Text] [PDF] J. Blade and L. Rosinol Changing paradigms in the treatment of multiple myeloma Haematologica, February 1, 2009; 94(2): 163 - 166. [Full Text] [PDF] D. Reece, J.-L. Harousseau, and M. A. Gertz Nontransplant Therapy of Myeloma, High-dose Therapy for Myeloma, and a Personalized Care Plan for Treatment of Myeloma ASCO Educational Book, January 1, 2009; 2009(1): 502 - 509. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020